Thrilled to share our new paper describing the development and characterization of CDK11 inhibitors for cancer therapy. We also establish a new system that I think represents a huge leap forward in our ability to understand drug toxicity in a living organism.

I’m thrilled to share that I’m joining the faculty at the Stanford University School of Medicine. My lab and I will be relocating to Stanford this summer!

If you're an international PhD student at Harvard working on something that my lab is familiar with and you're at risk of deportation, shoot me an email. We may be able to host you or find someone else who can.

The VC firm Lux Capital has launched a new $100M program to help scientists whose funding has been cut. Looks amazing - and I hope that more venture firms and philanthropies will follow their lead.

www.luxcapital.com/news/our-hel...

The 2025 Breakthrough Prize in Life Sciences was awarded to:

Drucker, Habener, Holst, Knudsen, and Mojsov for GLP-1/ozempic,

Hauser and Ascherio for treating multiple sclerosis,

and David Liu for CRISPR base editing.

Terrific choices!

breakthroughprize.org/News/91

For the first time since January, notification of a new NIH study section meeting has been posted on the Federal Register. It seems to cover multiple review panels, including one for the DP2/New Innovator grant.

www.federalregister.gov/agencies/nat...

Did you know - the medicine that President Trump takes each day to lower his risk of having a heart attack is a direct result of NIH funding? Let me explain -

What is the best degron tag that you can use to inducibly degrade a protein of interest in mice?

Congrats to Sheltzer Lab alum Vish Girish for being recognized on the #Forbes30Under30 list for Science!

www.forbes.com/30-under-30/...